Clostridium difficile Infection: Addressing Risk and Severity to Drive Treatment Choices
A CME-Certified Supplement to:
GI & Hepatology News
Release Date: November 2016
Expiration Date: November 30, 2017
Estimated Time to Complete Activity: 1.5 hours
Jointly provided by:
Supported by an educational grant from:
Merck Sharp & Dohme Corp.
This supplement is intended for gastroenterologists with an interest in improving management of Clostridium difficile infection (CDI). Other health care providers with an interest in CDI may also find this activity of interest.
Erik R. Dubberke, MD, MSPH
Ciaran P. Kelly, MD
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association (AGA) Institute and Strategic Consultants International (SCI). The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.
The AGA Institute designates this journal-based CME activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
Participants should read the CME information below, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designated and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time.
For CME questions please contact the AGA on: Education@gastro.org
For other inquiries please contact SCI on: firstname.lastname@example.org
Statement of Need
Clostridium difficile infection (CDI) is a serious complication of antibiotic therapy, although cases can also occur following person-to-person contact and in the community. Current guidelines for CDI generally recommend metronidazole (first line, mild symptoms) or vancomycin (first line, moderate or severe symptoms and for recurrence). However, both therapies are associated with recurrence. Patients with moderate or severe CDI with a poor prognosis and/or high risk of recurrence may benefit from therapies other than the standard guideline recommended first-line options, and it is now possible to risk score to help guide management. This activity will review the potential opportunities that risk-based management may have and research into novel therapies that may also benefit these high-risk patients.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Erik R. Dubberke, MD, MSPH
Consulting: Merck & Co., Inc., Sanofi Pasteur, Summit Pharmaceuticals International Corporation, Valneva
Ciaran P. Kelly, MD
Consulting: Merck, Seres Therapeutics, Inc.
Speaker fees: Merck, Seres Therapeutics
The Strategic Consultants International (SCI) planners Ian Morgan and Ana Costa reported no relationships to disclose.
The AGA Institute (AGA) planners Sandra Megally and Maura H. Davis reported no relationships to disclose.
Disclosure of Unlabeled Use
This activity includes discussion of agents not currently approved by the US Food and Drug Administration (FDA) for C. difficile, including some investigational agents.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other course of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contradictions on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This supplement was developed under the co-providership of the AGA Institute and Strategic Consultants International.
Neither the editors of GI & HEPATOLOGY NEWS, nor the Editorial Advisory Board, nor the reporting staff contributed to its content. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporter, joint providers, or of the Publisher.
Copyright © 2016 Global Academy for Medical Education, LLC, and Strategic Consultants International. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means without prior written permission of the Publisher. The Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including claims related to the products, drugs, or services mentioned herein.
Contact Information for Technical Questions
Please technical questions or concerns to Global Academy for Medical Education at 973-290-8225 or email email@example.com.